SCHEMBL6905562

SCHEMBL6905562

COc1cc(/C=C\c2ccc(O[Si](C)(C)C(C)(C)C)c(O[Si](C)(C)C(C)(C)C)c2O[Si](C)(C)C(C)(C)C)cc(OC)c1OC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 2/20 0.50
CYP1B1 Q16678 2/20 0.50
CYP1A2 P05177 1/20 0.50
TUBB1 Q9H4B7 10/20 0.48
TUBB4A P04350 7/20 0.47
TUBB P07437 7/20 0.47
TUBA3C P0DPH7 7/20 0.47
TUBA1B P68363 7/20 0.47
TUBA4A P68366 7/20 0.47
TUBB4B P68371 7/20 0.47
TUBB3 Q13509 7/20 0.47
TUBB2A Q13885 7/20 0.47
TUBB8 Q3ZCM7 7/20 0.47
TUBA3E Q6PEY2 7/20 0.47
TUBA1A Q71U36 7/20 0.47
TUBA1C Q9BQE3 7/20 0.47
TUBB6 Q9BUF5 7/20 0.47
TUBB2B Q9BVA1 7/20 0.47
MAOB P27338 3/20 0.46
MAOA P21397 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6905566 1.00 CYP1A1 (0.50) CYP1A1CYP1B1CYP1A2TUBB1TUBB4A
SCHEMBL6753698 0.96 CYP1A1 (0.52) CYP1A1CYP1B1CYP1A2TUBB1TUBB4A
SCHEMBL22455879 0.96 CYP1A1 (0.52) CYP1A1CYP1B1CYP1A2TUBB1TUBB4A
SCHEMBL6753697 0.96 CYP1A1 (0.52) CYP1A1CYP1B1CYP1A2TUBB1TUBB4A
SCHEMBL6900692 0.89 TUBB1 (0.50) CYP1A1CYP1B1CYP1A2TUBB1TUBB4A
SCHEMBL6900688 0.89 TUBB1 (0.50) CYP1A1CYP1B1CYP1A2TUBB1TUBB4A
SCHEMBL6904677 0.89 TUBB1 (0.51) CYP1A1CYP1B1CYP1A2TUBB1TUBB4A
SCHEMBL6904674 0.89 TUBB1 (0.51) CYP1A1CYP1B1CYP1A2TUBB1TUBB4A
SCHEMBL6906206 0.89 CYP1A1 (0.51) CYP1A1CYP1B1CYP1A2TUBB1TUBB4A
SCHEMBL6906209 0.89 CYP1A1 (0.51) CYP1A1CYP1B1CYP1A2TUBB1TUBB4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198302-B2 Anticancer agent having a quinone, quinone prodrug, catechol or catechol prodrug moiety; free of combretastatin A-1 OXIGENE, INC. (US) 2012-06-12 US disclosed
US-8198302-B2 Anticancer agent having a quinone, quinone prodrug, catechol or catechol prodrug moiety; free of combretastatin A-1 OXIGENE, INC. (US) 2012-06-12 US disclosed
US-20040242696-A1 Compositions and methods with enhanced therapeutic activity MATEON THERAPEUTICS, INC. 2004-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242696-A1 Compositions and methods with enhanced therapeutic activity NQO1, MKI67, COMT CYP1A1 809/4885CYP1B1 1230/4885CYP1A2 1187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.